Cont. Ch 1 Flashcards
DCQA
- Drug Compounding Quality Act
- Maintains regulation of traditional compounding with states under 503A
- BUT establishes 503B that allows facilities that are sterile compounding pharmaceuticals NOT based on patient specific prescriptions to register as “Outsourcing Facility”
Outsourcing Facilities
- Exempt from new drug provisions, adequate directions for use, and drug track/trace provisions
- Outsourcing Facilities are primarily regulated by FDA and subject to cGMPs
503A Facilities
- Compounding pharmacies
- May only compound pursuant to an individual prescription/med order
- Permitted to do limited anticipatory compounding
- Mainly regulated by states and subject to USP <797> (sterile)
Outsourcing Facilities MUST
- Have a licensed pharmacist to oversee
- Register with FDA (FDA provides lists of facilities with locations, if compound from bulk, and if the bulk is sterile/nonsterile)
- Report to Secretary of HHS upon registering and Q6Mo
- Inspection by FDA according to risk-based scheduled and pay annual fees
- Report serious AE within 15 days and conduct follow-up investigation/reporting similar to manufacturers
- Label products with a statement identifying them as compounded drug (w/ other specified drug info)
Outsourcing facilities may NOT include bulk substance unless…
- Bulk drug appears on list identifying of bulk drug substances for which there is a clinical need (503B bulk list)
- Drug product compounded from bulk appears on FDA’s shortage list at time of compounding, distribution, AND dispensing
Interstate Distribution of 503A Compounds
- Limits interstate distribution of compounded drug to <5% UNLESS state is in MOU with FDA
- Inordinate amount of compounded drugs is considered when number of Rx orders distributed interstate for human drugs is >50% sum of number of scripts ordered/sent out of facilities or number of orders dispensed in a calendar year
- *Texas has not entered MOU to date**
DSCSA
- Drug Supply Chain Security Act (Track and Trace)
- Uniform national framework for an electronic track/trace system for prescription drugs as they move through supply chain
- Sets national standards for states to license wholesalers
- Includes prescription drugs form human use in finished dosage form
- Provides Transaction Data passed from manufacturers to wholesalers to buyers
- Fully implemented by 2023
Exemptions to DSCSA
- Blood/blood components
- Radioactive drugs
- Imaging drugs
- IV Fluid replacement
- Dialysis soln
- Medical gases
- Compounded drugs
- Medical convenience kits with drugs
- Sterile water
- Irrigation products
Transaction Data Includes
- Transaction Information
- Transaction History
- Transaction Statement
Transaction Information
- Product Name/Strength/Dosage Form
- Date of Transaction
- Container size/number of containers
- Name/address of person to/from transferring
- Unique product identifier or serialized numerical identifier (SNI) - identifies an individual bottle/unit of sale (pharmacies may only receive drugs with this, don’t currently have to authenticate them)
Transaction History
- Paper or electronic statement
- Includes prior transaction information for each prior transaction back to the manufacturer
Transaction Statement (5)
-Paper or electronic statement by seller
States the following:
1. Seller is an authorized person to sent product
2. Received the transaction info/hx from prior owner if required
3. Did not knowingly ship a suspect/illegitimate product
4. Has systems/processes to comply with verification requirements
5. Did not knowingly provide false information
Suspect/Illegitimate Product Investigation
- MUST investigate and properly handle these products
- Pharmacy must verify the product identifier of at least 3 products or 10% of the suspect product (whichever is greater), OR all products if total number < 3
- Must verify any illegitimate product in notification to FDA/trading partner
- Notify FDA with FDA Form 3911 and notify trading partners within 24 hours
- Pharmacies should work with manufacturer to ensure products don’t reach the patients
Distributor Pharmacies
-Distributing drugs to anyone other than the consumer/patient
-Must have wholesale license and pass DSCSA transaction data with distribution
EXCEPTIONS to license/transaction data:
1. Distribution between two entities that are affiliated/under common ownership
2. Providing product to another dispenser on patient specific basis
3. Dispenser is distributing under emergency medical reasons
4. Distributing “minimal quantities” to licensed practitioner for office use
Animal Drugs
- FDA regulates drug intended to be used in animals
- Must be proven safe/effective
- FDA determines if they are prescriptions/OTC
- Can only be dispensed/ordered by veterinarians
- “Caution: Federal law restricts this drug to use by or on order of a licensed veterinarian”
- Vets can prescribe approved human drugs off-label for animals and these can be received/dispensed by pharmacies
- Guidance from FDA regarding compounding of animal drugs in specific circumstances
PPPA
- Poison Prevention Packaging Act of 1970
- Administered by CPSC (Consumer Product Safety Commission)
- Requires child-resistant containers for all prescriptions and certain nonRx drugs/preparations
ASA Child-Resistant Container Requirement
Human use in oral dosage form
Methyl Salicylate Child-Resistant Container Requirements
Liquid preps containing >=5% unless in pressurized spray containers
Methyl Alcohol Child-Resistant Container Requirements
Liquids containing >=4% unless in pressurized spray containers
Iron Child-Resistant Container Requirements
Exceptions are animal feed and human iron with a total amount equivalent to 250 mg of iron
Dietary Supplements with Iron Child-Resistant Container Requirements
- Contain 250 mg of iron or more
- Doesn’t include when iron is solely used as a colorant